BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) founder and CEO Tiffany Thorn speaks to Proactive's Thomas Warner after reporting positive results from a preclinical study of lead molecule BVX001, that she describes as "really exciting." Thorn explains the significance of the results and reveals how the business intends to move forward with the molecule having now established its "highly favourable" safety profile.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
